Table 2.

Measurements of urinary sodium excretion, potassium excretion, and 24-hour creatinine clearance at randomization and throughout the trial

MeasurementsPlaceboLosartanSpironolactone
Week 0
 n272627
 Urine Na (mEq/d)193 (82)220 (77)219 (127)
 Urine K (mEq/d)56 (18)63 (15)58 (19)
 Urinary creatinine clearance (ml/min)73 (59.6 to 89.4)64.8 (53 to 79.2)51.4 (40.1 to 65.8)
Week 24
 n222320
 Urine Na (mEq/d)223 (120)206 (86)220 (97)
 Urine K (mEq/d)59 (23)58 (16)54 (17)
 Urinary creatinine clearance (ml/min)67.5 (54.4 to 83.8)60.5 (49.6 to 73.7)48.1 (36.2 to 64.0)
Week 48
 n212117
 Urine Na (mEq/d)196 (107)213 (104)221 (101)
 Urine K (mEq/d)53 (22)52 (16)55 (22)
 Urinary creatinine clearance (ml/min)64.3 (49.6 to 83.4)54.1 (40.5 to 72.2)51.6 (39.6 to 67.4)
  • Data are listed as mean (SD) or geometric mean (95% confidence interval). All treatment comparisons are not significant for repeated measures analysis (urine Na, P=0.28; urine K, P=0.11; creatinine clearance, P=0.80).